Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07587008
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Emraclidine — DRUG
    Oral tablet

Study Details

The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.

Key Dates

Start date
May 12, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Sequence 1
    Participants will receive Emraclidine in 3 different formulations in Sequence 1.
  • Experimental: Sequence 2
    Participants will receive Emraclidine in 3 different formulations in Sequence 2.
  • Experimental: Sequence 3
    Participants will receive Emraclidine in 3 different formulations in Sequence 3.
  • Experimental: Sequence 4
    Participants will receive Emraclidine in 3 different formulations in Sequence 4.
  • Experimental: Sequence 5
    Participants will receive Emraclidine in 3 different formulations in Sequence 5.
  • Experimental: Sequence 6
    Participants will receive Emraclidine in 3 different formulations in Sequence 6.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to approximately 44 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 283349GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies